Skip to main content

Day: July 29, 2021

Workhorse Appoints Richard F. Dauch as Chief Executive Officer

CINCINNATI, July 29, 2021 (GLOBE NEWSWIRE) — Workhorse Group Inc. (NASDAQ: WKHS) (“Workhorse” or “the Company”), an American technology company focused on providing sustainable and cost-effective drone-integrated electric vehicles to the last mile delivery sector, announced today the appointment of Richard F. (“Rick”) Dauch as Chief Executive Officer (“CEO”), effective August 2nd, 2021. He will also join the Company’s Board of Directors. Dauch succeeds Duane Hughes who has served as CEO from February 2019 to August 1, 2021, and who previously served as Chief Operating Officer from August 2016 to January 2019. Hughes will continue to serve as a consultant through the transition period. Dauch previously served as the CEO of Delphi Technologies where he successfully completed the spin-off from Aptiv and then executed a merger with...

Continue reading

Vivos Therapeutics Opens State of the Art International Training Center In Denver

The Vivos Institute Is Expected to Significantly Increase Vivos’ Ability to Educate Healthcare Providers on Ways to Help Millions of People Suffering from Sleep Apnea and its Comorbidities HIGHLANDS RANCH, Colo., July 29, 2021 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that the Company has opened The Vivos Institute training center in Denver, Colorado. The 15,000-square-foot facility was established to provide advanced post-graduate education and training to dentists, dental teams and other healthcare providers from around the world in a live...

Continue reading

Alignment Healthcare Appoints Healthcare Veteran Afzal Shah to Lead Critical Medicare Advantage Market

ORANGE, Calif., July 29, 2021 (GLOBE NEWSWIRE) — Award-winning Medicare Advantage company Alignment Healthcare (NASDAQ: ALHC) today announced the appointment of senior health care executive Afzal Shah as senior vice president, California market president. In this role, Shah will be responsible for the overall performance in the company’s competitive California market. Currently, Alignment offers plans in 18 counties in California. “Afzal brings critical analytical skills that will drive business performance and also help us further expand our presence in our home market of California,” said Dawn Maroney, president of consumer & markets and CEO, Alignment Health Plan. “His strong background in Medicare and years of experience spearheading high impact health care initiatives is a strong addition to our growing leadership team.” Shah...

Continue reading

Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387

Data Shows AUG-3387 Neutralizes SARS-CoV-2 Delta Variant in Infective Assays Supports Earlier Data Showing AUG-3387 Binds Strongly to Delta Variant in Addition to Wild-Type Spike Protein and Other Variants of Concern Catalent Selected as Contract Drug Manufacturing Organization (CDMO) for AUG-3387 Scale-up Manufacturing for AUG-3387 Proceeding Rapidly; Early Batches Show Promising Results MENLO PARK, Calif. and AUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) — Augmenta Bioworks, a biotechnology company enabling breakthroughs in medicine through immune profiling, and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced positive in vitro data indicating...

Continue reading

Independent Bank Corporation Reports 2021 Second Quarter Results

GRAND RAPIDS, Mich., July 29, 2021 (GLOBE NEWSWIRE) — Independent Bank Corporation (NASDAQ: IBCP) reported second quarter 2021 net income of $12.4 million, or $0.56 per diluted share, versus net income of $14.8 million, or $0.67 per diluted share, in the prior-year period. For the six months ended June 30, 2021, the Company reported net income of $34.4 million, or $1.56 per diluted share, compared to net income of $19.6 million, or $0.88 per diluted share, in the prior-year period. The decline in second quarter 2021 earnings as compared to 2020 primarily reflects a decrease in non-interest income and an increase in non-interest expense that were partially offset by an increase in net interest income and decreases in the provision for credit losses and income tax expense. The increase in year-to-date 2021 earnings as compared to...

Continue reading

DraftKings and Sports & Social Enter Into Strategic Sports Betting and Entertainment Agreement

Deal to create unique, in-person luxury entertainment experience for DraftKings and Sports & Social customers BOSTON and BALTIMORE, July 29, 2021 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) and national entertainment concept, Sports & Social, announced today a strategic new relationship to create upscale Sports & Social/DraftKings sports bars beginning in the Nashville and Detroit markets, pending regulatory approvals. The collaboration brings together Sports & Social’s market leadership in operating high-energy, first-class dining and entertainment venues with DraftKings’ top-rated and industry-leading sports gaming platforms. Together, the integration forms one of the most exciting new offerings in sports betting and entertainment for DraftKings and Sports & Social fans across the nation. The Sports...

Continue reading

SANUWAVE Announces Collaboration with NASA for the Mitigation of Bacterial Biofilms Formed in the Water Processor Assembly used on International Space Station (ISS) and for Future Moon Base and Mars Colony

SUWANEE, GA, July 29, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — SANUWAVE Health, Inc. (OTCQB: SNWV), announces collaboration with National Aeronautics and Space Administration (NASA).  One of the most important objectives of this decade for National Aeronautics and Space Administration (NASA) is the restart of missions to the Moon to establish a Lunar Base.  This is just the first step for further exploration of other celestial bodies and resources, with the focus on Mars, where the First Human Mars Colony will be constructed in the following decades.  The initial training and observation of the influence of extraterrestrial non-gravitational or low gravitational environment on the human body for long periods of time was done onboard of the International Space Station (ISS), where a plethora of cosmonauts from all over the...

Continue reading

AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson’s Disease at AAIC 2021

ACI-24 generated an encouraging immune response that correlated with a signal of target engagement in patients with Down syndrome (DS) Full Phase 1b results support the continued clinical development of anti-Abeta vaccine approaches in DS-related Alzheimer’s disease (AD) LAUSANNE, Switzerland, July 29, 2021 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today outlined two presentations being delivered at the Alzheimer’s Association International Conference (AAIC) 2021, taking place both in Denver, USA and virtually from July 26-30, 2021. The presentations highlight precision medicine approaches to enable the early detection and prevention of neurodegenerative diseases by targeting amyloid beta (Abeta) and alpha-synuclein (a-syn)....

Continue reading

Saia Reports Record Second Quarter Results

JOHNS CREEK, Ga., July 29, 2021 (GLOBE NEWSWIRE) — Saia, Inc. (Nasdaq: SAIA), a leading transportation provider offering national less-than-truckload (LTL), non-asset truckload, expedited and logistics services, today reported second quarter 2021 financial results. Diluted earnings per share in the quarter were $2.34 compared to $1.07 in the second quarter of 2020. Highlights from the second quarter operating results were as follows: Second Quarter 2021 Compared to Second Quarter 2020 ResultsRevenue was $571.3 million, a 36.6% increase Operating income was $82.9 million, a 132.4% increase Operating ratio of 85.5 compared to 91.5 LTL shipments per workday increased 15.3% LTL tonnage per workday increased 23.1% LTL revenue per hundredweight increased 10.5% LTL revenue per shipment rose 17.9% to $277“It is great to report record...

Continue reading

Progenity Announces Successful Completion of Clinical Validation Study and Achievement of the Primary Endpoint for its Preeclampsia Rule-Out Test

The company’s Preecludia™ test performed strongly in a broad, intended-use population SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today successful completion of the validation study for its Preecludia™ rule-out test for preeclampsia and achievement of the primary endpoint of the study protocol. The PRO-104 clinical validation study was a prospective, multi-center, observational study with over 1,300 enrolled subjects. Test specimens were collected from pregnant patients aged 18 to 45 years and 28 0/7 to 36 6/7 weeks’ gestational age. Analysis was blinded. Patients in the study cohort presented with potential signs and symptoms of preeclampsia at 20 labor and delivery triage sites across all major regions of the United States. Patient demographics were...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.